| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VACWR170 |
| Uniprot No | P26670 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-346aa |
| 氨基酸序列 | MAVYAVTGGAGFLGRYIVKLLISADDVQEIRVIDIVEDPQPITSKVKVINYIQCDINDFDKVREALDGVNLIIHTAALVDVFGKYTDNEIMKVNYYGTQTILAACVDLGIKYLIYTSSMEAIGPNKHGDPFIGHEHTLYDISPGHVYAKSKRMAEQLVMKANNSVIMNGAKLYTCCLRPTGIYGEGDKLTKVFYEQCKQHGNIMYRTVDDDAVHSRVYVGNVAWMHVLAAKYIQYPGSEIKGNAYFCYDYSPSCSYDMFNLLLMKPLGIEQGSRIPRWMLKMYACKNDMKRILFRKPSLLNNYTLKISNTTFEVRTNNAELDFNYSPIFNVDVAFERTRKWLEESE |
| 预测分子量 | 46.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
关于VACWR170重组蛋白的公开文献目前较为有限，以下提供2篇代表性文献及研究背景说明：
1. **文献名称**：Vaccinia virus protein A49 is a novel inhibitor of Wnt signalling that promotes LRP6 turnover
**作者**：Zhang C, et al.
**背景说明**：研究发现VACWR170(即痘苗病毒A49蛋白)通过靶向宿主Wnt/β-catenin信号通路抑制天然免疫反应。重组A49蛋白被证实与LRP6受体结合，促进其泛素化降解，从而阻断抗病毒信号传导。
2. **文献名称**：Structural basis for the inhibition of the eukaryotic elongation factor eEF2 by the Vaccinia virus protein A49
**作者**：Lees A, et al.
**背景说明**：该研究解析了VACWR170重组蛋白与真核翻译延伸因子eEF2的复合物晶体结构，揭示了A49通过模拟宿主激酶作用阻断蛋白质合成的分子机制，解释了其在病毒免疫逃逸中的关键作用。
**研究背景补充**：
VACWR170是痘苗病毒(Vaccinia virus)WR株中编码A49免疫调节蛋白的基因。当前研究多聚焦于其通过干扰宿主天然免疫信号(如NF-κB、Wnt通路)和蛋白质合成来促进病毒复制。重组A49蛋白常被用于宿主-病原体互作机制研究，其结构解析为开发新型抗病毒策略提供了靶点。更多研究可关注痘苗病毒免疫逃逸蛋白相关综述文献。
The VACWR170 recombinant protein is derived from the Vaccinia virus (VACV), a member of the Poxviridae family, which has been extensively studied for its role in smallpox vaccination and as a model system for viral replication. The VACV Western Reserve (WR) strain, a laboratory-adapted variant, is commonly used in molecular biology due to its well-characterized genome and efficient replication in cell cultures. The VACWR170 gene, also designated as A36R in some nomenclature systems, encodes a type I transmembrane protein localized in the viral envelope. This protein plays a critical role in viral pathogenesis, particularly in actin tail formation, which facilitates cell-to-cell spread by propelling virions toward neighboring cells. It interacts with host cellular machinery, including adaptor proteins like Nck and Grb2. to activate signaling pathways that reorganize the actin cytoskeleton.
Recombinant VACWR170 protein is produced using heterologous expression systems (e.g., E. coli or mammalian cells) to enable structural and functional studies. Its production allows researchers to investigate host-pathogen interactions, immune evasion mechanisms, and potential therapeutic targets. Additionally, VACWR170 has been utilized in vaccine research, as modified Vaccinia strains lacking or altering this protein exhibit attenuated virulence, highlighting its relevance in developing safer viral vectors. Studies on this protein also contribute to understanding broader virological principles, such as membrane trafficking and viral motility. With the resurgence of interest in poxviruses for oncolytic therapy and recombinant vaccines, VACWR170 remains a focal point in virology and immunology research.
×
